|
|
12 Health Care Stocks Moving In Friday's After-Market Session
|
|
|
|
AIM ImmunoTech shares are trading lower after the company announced a $12 million rights offering.
|
|
|
|
AIM ImmunoTech Commences $12M Rights Offering; Stock Holders To Purchase One Unit And 1,666 Warrants To Purchase Common Stock At $1,000/Unit
|
|
|
|
12 Health Care Stocks Moving In Monday's After-Market Session
|
|
|
|
12 Health Care Stocks Moving In Monday's Intraday Session
|
|
|
|
12 Health Care Stocks Moving In Thursday's Intraday Session
|
|
|
|
AIM ImmunoTech shares are trading higher after the company reported year-end data from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi for the treatment of pancreatic cancer.
|
|
|
|
Nasdaq Dips 200 Points; Alphabet Posts Upbeat Earnings
|
|
|
|
AIM ImmunoTech Reports Data From Ongoing Phase 2 Clinical Study Evaluating Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi For Metastatic Pancreatic Cancer Treatment
|
|
|
|
12 Health Care Stocks Moving In Wednesday's After-Market Session
|
|